Key Takeaways
- Oura postponed its IPO on Tuesday 29 September, hours before it was due to price and a day before it was due to trade on the Nasdaq, citing "uncertainty in the IPO market", even though orders reportedly ran to about four times the 50 million shares on offer.
- Why a 4x-oversubscribed deal still failed: heavy demand at the marketed range isn't the same as demand at the top of it. Investors reportedly balked at $44 a share, and with 73% of the shares being sold by insiders, the sellers wanted top price. A spike in bond yields and oil volatility did the rest.
- The lesson, live: oversubscription measures interest in a deal at a price; it is not a forecast for the stock, and, as this week showed, not even a guarantee the listing happens.
- The bigger signal: it's the third big US IPO postponement this month. After a strong start to 2026, the listing window is narrowing on a Fed rate hike, 5%+ bond yields, geopolitics and doubts about the AI trade.
- The business hasn't changed: Oura is profitable ($60.8 million of net income over nine months), expects revenue up 90% this fiscal year, and now has 5.7 million paid members.
- When it does list, you'll be able to buy Oura shares on Nemo.money from just $1 with zero commission, alongside global stocks and ETFs.
It was supposed to be the autumn's blockbuster listing. Oura, maker of the $400 smart ring, was due to price its $2.2 billion IPO on Tuesday night and start trading on the Nasdaq on Wednesday, with orders reportedly running to four times the shares available. Instead, on Tuesday morning, the company announced it was postponing the deal, "despite strong demand, due to uncertainty in the IPO market."
For anyone who had read the headlines about "everyone wanting in," the news is jarring. It's also one of the most useful lessons the IPO market has delivered this year, because it shows exactly why a hot order book doesn't guarantee a listing, let alone a good investment. This guide explains what happened, why the deal fell apart at the last minute, what it signals about the IPO market, and what happens next. It's educational, not investment advice, and OURA is an example to research, not a recommendation. (For the background, see our earlier pieces on what a hot IPO really means and the IPO terms and Eli Lilly's backing.) If it prompts you to research the theme, you can explore global stocks and ETFs from just $1 with zero commission on the Nemo.money app.
People are searching:
- "Oura IPO delayed"
- "why did Oura postpone IPO"
- "Oura IPO"
- "when will Oura IPO"
- "how to buy Oura stock"
- "buy Oura shares UAE"
- "Oura stock Nemo"
- "OURA ticker"
- "is Oura profitable"
- "what does oversubscribed mean IPO"
- "IPO market September 2026"
- "biggest IPO 2026"
What Happened
The facts, as reported:
- 🛑 Postponed at the last minute. In a statement on Tuesday 29 September, Oura said it was postponing its IPO "despite strong demand, due to uncertainty in the IPO market." The deal had been scheduled to price that evening and to begin trading on the Nasdaq under the ticker OURA on Wednesday. No new date was given.
- 📈 The demand was real. Bloomberg reported last week that orders ran to roughly four times the 50 million shares on offer (one source told Axios it was closer to five). The books closed on Monday afternoon. On paper, this was the most in-demand US listing since the summer.
- 💵 The terms that didn't get done. 50 million shares at a marketed range of $40-44, to raise up to about $2.2 billion at a fully diluted valuation of around $15.6 billion at the top. Only 13.5 million shares were new; 36.5 million (73%) were to be sold by existing investors such as Forerunner Ventures and Lifeline Ventures. Eli Lilly had indicated interest in up to $100 million and Dragoneer up to $300 million.
- 🗣️ What Oura said. CEO Tom Hale: "Our mission is to empower people to live healthier, longer, and an IPO is just one step in our journey. We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment." The company added that it is profitable, expects fiscal 2026 revenue to grow 90%, and that "exceptionally strong" demand for the Oura Ring 5 has taken paid members to 5.7 million.
- 📅 The pattern. Oura is the third sizeable US IPO to be pulled this month, after Holtec Nuclear (since withdrawn) and Bamboo Insurance, with others quietly slipping. After a quiet September, this was to have been the first US IPO to raise more than $1 billion since Jersey Mike's Subs in July.
Why a 4x-Oversubscribed Deal Still Didn't Get Done
This is the part worth understanding, because it corrects a common misreading of IPO headlines.
- 🎯 Demand at a range is not demand at the top of it. "Four times oversubscribed" meant investors had asked for four times the shares at some price within $40-44. According to a source familiar with the process cited by Axios, plenty of that demand evaporated at the top of the range. Oura, in short, couldn't get the price it wanted.
- 🧾 The seller wanted top dollar. Because 73% of the shares were being sold by early investors rather than the company, the deal was unusually price-sensitive: those sellers were cashing out and had every incentive to hold for $44 rather than accept $40. A company raising growth capital can be more flexible; a syndicate of insiders exiting is less so.
- 📉 The market moved underneath it. In the days before pricing, the US 10-year Treasury yield hit 5.2%, a 19-year high, oil swung on Middle East news, the Federal Reserve had just surprised markets with a rate hike, and investors began questioning how long the AI trade can run. Higher yields make richly valued growth stocks less attractive overnight, and IPO buyers demand a bigger discount to compensate.
- 💰 Valuation doubts were already there. Analysts had flagged the ~10-times-revenue price tag as rich for a company still making 80% of its money from hardware. One IPO analyst quoted by Reuters described 4x as "a decent level of demand, but not necessarily overwhelming for a well-known consumer brand."
- ⏸️ Postponing beats a bad print. Pricing below the range, or seeing the stock fall on day one, would have damaged Oura's brand with investors for years. Pulling the deal and waiting for a calmer window is the textbook move when the book is soft at the top, and it's what Oura chose.
The Lesson: Oversubscription Is a Fact, Not a Forecast
We made this point before the postponement; the market has now made it for us.
- 🎟️ What "oversubscribed" measures. Interest in a deal, at a marketed price, on a given day. It usually pushes pricing toward the top of the range and means retail applicants get few or no shares at the IPO price.
- 🔮 What it doesn't measure. Whether the business will grow into its valuation, how the stock trades after lock-ups expire, or, as Oura showed, whether the deal even completes. Some of the most oversubscribed IPOs in history opened with huge pops and spent years below their debut price; others never made it to the tape. Even SpaceX's record listing, which jumped 19% on day one, has swung sharply on hype since. (Our IPO 101 guide covers how new listings tend to perform over time.)
- 🧠 The takeaway for investors. Treat "hot demand" headlines as information about the deal's marketing, not about the investment. The questions that matter are the boring ones: what's the business worth, what are you paying, and who's selling.
Why Everyone Wanted In (and Still Might)
None of the reasons investors queued up have gone away; the postponement is about price and timing, not the business:
- 💰 It's profitable. Oura reported $60.8 million of net income on $1.21 billion of revenue for the nine months to June 2026 (about $59 million on $1.43 billion over the trailing 12 months), with $328 million of operating cash flow. That's rare for consumer hardware at IPO. (The "$924 million loss" in some headlines is an accounting charge from repurchasing early investors' preferred stock before the IPO, not an operating loss.)
- 🔁 Subscriptions are the story. Membership revenue grew 121% year on year to $240 million at an ~89% gross margin, and over 94% of ring buyers convert to paid members. Oura's CEO has pitched it as "a subscription company that happens to sell hardware."
- 📊 The growth is accelerating. Revenue up 74%, paid members now 5.7 million (up from 5 million at the end of June), a 90% revenue-growth forecast for the fiscal year, and roughly 79% of the global smart-ring market.
- 🧬 Health-tech crossover. Eli Lilly's involvement (a $50 million investment plus indicated IPO interest) and more than 1,200 health integrations position Oura as a health-data platform, not just a gadget. Whether Wall Street values it that way, rather than as consumer electronics, is precisely what the IPO was meant to test.
What Happens Next
The postponement opens several paths:
- 🗓️ A relaunch. Oura says it has "the luxury of choosing our moment." Watch for a revived deal once markets settle, potentially with a reset price range. Companies that postpone often return within weeks or months; some wait a year or more.
- 💵 A lower price, or fewer secondary shares. The cleanest fix for a book that's soft at the top is a lower range, or a deal with more new shares and fewer insider sales, both of which would change the maths for buyers.
- 🏦 Private money instead. With Eli Lilly already invested and profitability in hand, Oura could raise privately and wait. A profitable company doesn't need to list on a bad day.
- 🧪 The read-across for other IPOs. Oura's postponement is a signal that the window has narrowed. The next tests will be how other deals fare in October and whether the giants, including Anthropic, now expected to headline the second half of the year, possibly after the November US midterms, and eventually OpenAI, proceed on schedule.
- ⌚ The competition doesn't pause. Samsung, Whoop, Google and Apple, reportedly developing a screenless health band of its own, keep moving while Oura waits.
The Honest Risks
- ⚠️ No date. Oura hasn't said when it will try again, and postponed IPOs sometimes never return.
- ⚠️ A lower valuation next time. If markets stay volatile, a relaunch may come at a lower price, good for new buyers, but a sign the $15 billion target was a stretch.
- ⚠️ Secondary-heavy structure. 73% insider selling was part of why the deal was hard to price; it remains a feature investors should weigh.
- ⚠️ Thin, recent profits. A ~5% net margin, profitability only since fiscal 2025, a prospectus warning of "no assurance" it lasts, and $375 million of debt drawn partly to fund the pre-IPO buyout of early investors.
- ⚠️ Competition and a legal cloud. Deep-pocketed rivals, and a proposed class action over sleep-tracking accuracy (which Oura contests).
- ⚠️ Hype cuts both ways. The same headlines that drew a crowd last week are now reading "pulled." Sentiment around new listings can turn in days.
The takeaway: Oura's business is largely what it was a week ago, profitable, fast-growing, well-backed. What changed is the price investors would pay and the market they'd pay it in. That's the whole lesson of this episode: demand is a fact about a deal at a price; it's not a forecast, and, this week, not even a guarantee of a listing.
How to Buy Oura Stock on Nemo.money (When It Lists)
Oura hasn't set a new IPO date, so there's no OURA stock to buy yet. When it does list on the Nasdaq under the ticker OURA, you'll be able to buy it on the Nemo.money app, alongside thousands of US-listed stocks and ETFs. A few things worth knowing:
- Buy from Just $1: Fractional shares mean you don't need to buy a whole share, useful when a newly listed stock is volatile and you'd rather start small.
- Zero-Commission Trading: Buy and sell US-market stocks and ETFs without commission fees.
- Market price, not IPO price: Like most investing apps, Nemo doesn't offer IPO allocations, so you'd be buying once trading begins, at the market price, which can differ substantially from any IPO price in the early days.
- AI-Powered Insights & Nemes: Explore data, sentiment and curated themed collections (Nemes), including technology, health and wearables themes, as a research starting point.
- Earn 6% AER on Idle Cash: Uninvested cash in your wallet earns 6% AER, paid daily in USD, while you wait and research.
Being able to buy a stock isn't a reason to buy it: OURA is an example to research, not a recommendation, and your capital is at risk.
Frequently Asked Questions (FAQs)
Why did Oura postpone its IPO?
Oura said on 29 September 2026 that it was postponing its IPO "despite strong demand, due to uncertainty in the IPO market," hours before the deal was due to price. According to a source cited by Axios, the company couldn't get the price it wanted: although orders ran to roughly four times the shares on offer, investors weren't willing to buy at the top of the $40-44 range, and because 73% of the shares were being sold by early investors, the sellers were reluctant to accept less. A spike in bond yields, oil volatility, a Fed rate hike and doubts about the AI trade had unsettled markets in the days before.
When will Oura IPO now?
Oura hasn't given a new date. CEO Tom Hale said the company has "the luxury of choosing our moment," suggesting it will relaunch when markets are calmer, possibly with a revised price range. Companies that postpone IPOs often return within weeks or months, but some wait far longer, and a few never list. Watch for a new filing or roadshow announcement. Any eventual listing would be on the Nasdaq under the ticker OURA.
Was Oura's IPO oversubscribed?
Yes. Bloomberg reported orders for about four times the 50 million shares on offer (one source put it nearer five). But oversubscription measures interest at some price within the marketed range, not at the top of it, and not for the long term. In Oura's case, demand reportedly thinned at $44 a share, which, combined with volatile markets and a secondary-heavy deal structure, led the company to postpone rather than price low. It's a clear example of why a hot order book doesn't guarantee a listing, let alone a strong stock.
Is Oura profitable?
Yes, on a net income basis. Oura's prospectus shows net income of $60.8 million on revenue of $1.21 billion for the nine months to 30 June 2026 (about $59 million on $1.43 billion over the trailing 12 months), with $71.2 million of operating income and $328 million of operating cash flow. Profitability is recent: it roughly broke even in fiscal 2025 and earned $3.6 million in fiscal 2024, and the prospectus warns there's no assurance it will continue. The "$924 million loss" seen in some headlines is the loss attributable to common stockholders after a $985 million accounting charge (a "deemed dividend") from repurchasing early investors' preferred stock before the IPO. It is not an operating loss.
What does Oura's postponement mean for the IPO market?
It's a warning sign. Oura is the third sizeable US IPO to be pulled in September 2026, after a strong first half of the year, as rising bond yields (the 10-year hit 5.2%), a Federal Reserve rate hike, geopolitical tension and doubts about AI spending have made investors more price-sensitive. A profitable, in-demand consumer company failing to price suggests the window for new listings has narrowed. The next tests are October's deals and whether mega-listings such as Anthropic's, expected in the second half of the year, proceed on schedule.
How can I buy Oura stock?
Not yet: Oura has postponed its IPO and hasn't set a new date, so there's no OURA stock to buy. If and when Oura lists on the Nasdaq under the ticker OURA, you'll be able to buy it through an investing app or brokerage that offers US-listed stocks. On Nemo.money, OURA would be available from $1 (via fractional shares) with zero commission once trading begins, at the market price rather than the IPO price. Newly listed shares are often volatile in their first days and weeks. Any decision is an example to research, not a recommendation, and your capital is at risk.
Final Thoughts: The Deal Changed, the Lesson Didn't
A week ago, Oura was the hottest IPO of the autumn: a profitable, fast-growing health company with a four-times-covered order book and retail investors queuing through their apps. On Tuesday it became the clearest lesson of the season instead, that a crowd at the door doesn't mean a sale at the price the seller wants.
The business is essentially unchanged; what shifted was the market beneath it, bond yields at a 19-year high, a Fed that's hiking, oil that won't sit still, and buyers who suddenly wanted a bigger discount. For a deal dominated by insiders looking to cash out at the top of the range, that gap was enough. Oura will almost certainly be back, perhaps at a price that suits buyers better. In the meantime, the discipline is the same one we've argued all along, only now with the proof attached: judge the business, not the queue, and remember that demand is a fact about a deal on a day, never a forecast.
Explore global stocks and ETFs from $1 with zero commission on the Nemo.money app.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#Oura #IPO #Investing #Wearables #NemoMoney
Terms and conditions apply. This is not investment advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
